Penta Foundation
@pentafoundation.bsky.social
The Penta Foundation is a global leader in paediatric infectious disease research. We're committed to developing innovative solutions to protect the health of children and pregnant people worldwide.
💻 https://penta-id.org/
💻 https://penta-id.org/
🧵
📢 NEWS: Kenya joins @gardp.bsky.social NeoSep1 Part 2 trial on #NeonatalSepsis.
The trial has started enrolling newborn babies with #sepsis at Kilifi County Hospital (Kilifi) Coast General Teaching & Referral Hospital (Mombasa) and Mbagathi Hospital (Nairobi). 🇰🇪
📢 NEWS: Kenya joins @gardp.bsky.social NeoSep1 Part 2 trial on #NeonatalSepsis.
The trial has started enrolling newborn babies with #sepsis at Kilifi County Hospital (Kilifi) Coast General Teaching & Referral Hospital (Mombasa) and Mbagathi Hospital (Nairobi). 🇰🇪
Treating neonatal sepsis
YouTube video by Penta Child Health Research
youtube.com
February 15, 2026 at 7:16 AM
🧵
📢 NEWS: Kenya joins @gardp.bsky.social NeoSep1 Part 2 trial on #NeonatalSepsis.
The trial has started enrolling newborn babies with #sepsis at Kilifi County Hospital (Kilifi) Coast General Teaching & Referral Hospital (Mombasa) and Mbagathi Hospital (Nairobi). 🇰🇪
📢 NEWS: Kenya joins @gardp.bsky.social NeoSep1 Part 2 trial on #NeonatalSepsis.
The trial has started enrolling newborn babies with #sepsis at Kilifi County Hospital (Kilifi) Coast General Teaching & Referral Hospital (Mombasa) and Mbagathi Hospital (Nairobi). 🇰🇪
Today is the #InternationalDayOfWomenAndGirlsInScience and we asked the women within the Penta ID Network to share a message for girls who are interested in STEM but are hesitant to take that step.
Watch for a dose of inspiration from the women leading by example.
Watch for a dose of inspiration from the women leading by example.
February 11, 2026 at 11:19 AM
Today is the #InternationalDayOfWomenAndGirlsInScience and we asked the women within the Penta ID Network to share a message for girls who are interested in STEM but are hesitant to take that step.
Watch for a dose of inspiration from the women leading by example.
Watch for a dose of inspiration from the women leading by example.
📢 Call for Abstracts: 𝟭𝟴𝘁𝗵 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗼𝗻 #PediatricsHIV 𝟮𝟬𝟮𝟲! Submission deadline: 17 April 2026.
Join fellow researchers and clinicians to advance #HIV prevention and treatment for infants, children and adolescents.
🔗 Learn more and submit your abstract: lnkd.in/d43EaECG
Join fellow researchers and clinicians to advance #HIV prevention and treatment for infants, children and adolescents.
🔗 Learn more and submit your abstract: lnkd.in/d43EaECG
February 10, 2026 at 12:58 PM
📢 Call for Abstracts: 𝟭𝟴𝘁𝗵 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗼𝗻 #PediatricsHIV 𝟮𝟬𝟮𝟲! Submission deadline: 17 April 2026.
Join fellow researchers and clinicians to advance #HIV prevention and treatment for infants, children and adolescents.
🔗 Learn more and submit your abstract: lnkd.in/d43EaECG
Join fellow researchers and clinicians to advance #HIV prevention and treatment for infants, children and adolescents.
🔗 Learn more and submit your abstract: lnkd.in/d43EaECG
Big news from the PIPELINE team!
We’ve officially recruited our first participant into the PIPELINE RSV-International trial.
This milestone marks the start of an important chapter bringing us closer to providing better protection against RSV in infants.
More 👉 bit.ly/3O3qsdP
We’ve officially recruited our first participant into the PIPELINE RSV-International trial.
This milestone marks the start of an important chapter bringing us closer to providing better protection against RSV in infants.
More 👉 bit.ly/3O3qsdP
February 9, 2026 at 1:59 PM
Big news from the PIPELINE team!
We’ve officially recruited our first participant into the PIPELINE RSV-International trial.
This milestone marks the start of an important chapter bringing us closer to providing better protection against RSV in infants.
More 👉 bit.ly/3O3qsdP
We’ve officially recruited our first participant into the PIPELINE RSV-International trial.
This milestone marks the start of an important chapter bringing us closer to providing better protection against RSV in infants.
More 👉 bit.ly/3O3qsdP
⏰ Last chance to submit your abstract for the 3rd Conference on Innovations in Tuberculosis - highlighting TB research and innovation in African contexts, where the burden is greatest but voices are too often underrepresented.
Info & submit abstract ➡️ bit.ly/4tmOp00
@academicmededu.bsky.social
Info & submit abstract ➡️ bit.ly/4tmOp00
@academicmededu.bsky.social
February 4, 2026 at 3:26 PM
⏰ Last chance to submit your abstract for the 3rd Conference on Innovations in Tuberculosis - highlighting TB research and innovation in African contexts, where the burden is greatest but voices are too often underrepresented.
Info & submit abstract ➡️ bit.ly/4tmOp00
@academicmededu.bsky.social
Info & submit abstract ➡️ bit.ly/4tmOp00
@academicmededu.bsky.social
The #ENABLE kick-off meeting is underway in South Africa! @globalhealthedctp3.bsky.social
Penta will coordinate Ethics & Regulatory work for a trial testing 2 #bNAbs as intensification therapy alongside oral #ART in high-risk infants with #HIV 👶🏽
Excited to be part of this impactful project 🥰
Penta will coordinate Ethics & Regulatory work for a trial testing 2 #bNAbs as intensification therapy alongside oral #ART in high-risk infants with #HIV 👶🏽
Excited to be part of this impactful project 🥰
February 4, 2026 at 10:52 AM
The #ENABLE kick-off meeting is underway in South Africa! @globalhealthedctp3.bsky.social
Penta will coordinate Ethics & Regulatory work for a trial testing 2 #bNAbs as intensification therapy alongside oral #ART in high-risk infants with #HIV 👶🏽
Excited to be part of this impactful project 🥰
Penta will coordinate Ethics & Regulatory work for a trial testing 2 #bNAbs as intensification therapy alongside oral #ART in high-risk infants with #HIV 👶🏽
Excited to be part of this impactful project 🥰
Did you know that low-risk children often receive the same antibiotic treatment as high-risk patients? This is because we lack clear data on when to safely stop care
PediSEP-1 aims to change that and provide the missing data, inform policy change and protect children from #AMR!
PediSEP-1 aims to change that and provide the missing data, inform policy change and protect children from #AMR!
Right-sizing antibiotic treatment, highlights from the PediSEP-1 kick-off meeting - PediSEP-1
From January 19–20, 2026, the PediSEP-1 consortium gathered in Mombasa, Kenya, for the official launch the project, designed to move paediatric care away from a “one-size-fits-all” approach and toward...
pedisep1.org
January 30, 2026 at 2:30 PM
Did you know that low-risk children often receive the same antibiotic treatment as high-risk patients? This is because we lack clear data on when to safely stop care
PediSEP-1 aims to change that and provide the missing data, inform policy change and protect children from #AMR!
PediSEP-1 aims to change that and provide the missing data, inform policy change and protect children from #AMR!
PIPELINE RSV International has officially opened its first site!
Can we better protect babies and pregnant people from #RSV? PIPELINE RSV hopes to answer this.
Swipe to learn more!
Read the full announcement here 👉 bit.ly/45mhtdH
Can we better protect babies and pregnant people from #RSV? PIPELINE RSV hopes to answer this.
Swipe to learn more!
Read the full announcement here 👉 bit.ly/45mhtdH
January 23, 2026 at 9:58 AM
PIPELINE RSV International has officially opened its first site!
Can we better protect babies and pregnant people from #RSV? PIPELINE RSV hopes to answer this.
Swipe to learn more!
Read the full announcement here 👉 bit.ly/45mhtdH
Can we better protect babies and pregnant people from #RSV? PIPELINE RSV hopes to answer this.
Swipe to learn more!
Read the full announcement here 👉 bit.ly/45mhtdH
Reposted by Penta Foundation
📈 New NeoSep1 results!
Part 1 shows that fosfomycin and flomoxef are safe and well-tolerated in babies with sepsis. Part 2, designed by our experts, compares antibiotic combinations for treating neonatal sepsis.
@pentafoundation.bsky.social @gardp.bsky.social
Read more about it 👇
Part 1 shows that fosfomycin and flomoxef are safe and well-tolerated in babies with sepsis. Part 2, designed by our experts, compares antibiotic combinations for treating neonatal sepsis.
@pentafoundation.bsky.social @gardp.bsky.social
Read more about it 👇
Every year, sepsis claims hundreds of thousands of newborn lives, but new evidence offers hope. 👶
#NeoSep1 Part 1 shows off-patent antibiotics fosfomycin and flomoxef are safe and well tolerated in newborns with suspected #sepsis, including high-risk preterm infants. 💜
👇
#NeoSep1 Part 1 shows off-patent antibiotics fosfomycin and flomoxef are safe and well tolerated in newborns with suspected #sepsis, including high-risk preterm infants. 💜
👇
NeoSep1 Part 1 study shows promising antibiotic options for newborns with suspected sepsis - SNIP-AFRICA
A paper published in the journal Antimicrobial Agents and Chemotherapy (AAC) reports that off-patent antibiotics, fosfomycin and flomoxef, when used at standard doses, were safe in newborn babies with...
www.snip-africa.org
January 15, 2026 at 3:26 PM
📈 New NeoSep1 results!
Part 1 shows that fosfomycin and flomoxef are safe and well-tolerated in babies with sepsis. Part 2, designed by our experts, compares antibiotic combinations for treating neonatal sepsis.
@pentafoundation.bsky.social @gardp.bsky.social
Read more about it 👇
Part 1 shows that fosfomycin and flomoxef are safe and well-tolerated in babies with sepsis. Part 2, designed by our experts, compares antibiotic combinations for treating neonatal sepsis.
@pentafoundation.bsky.social @gardp.bsky.social
Read more about it 👇
📣 Healthcare professionals: level up your expertise in #HIV & congenital infections 🇮🇹!
🎓 PentaTr@ining course (hybrid): online modules + expert webinars + in-person workshop in Padova, Italy
🗓 Online Apr–Jul 2026 | Residential Sept 2026
🔗 Register now 👉 penta-id.org/hiv-other-co...
🎓 PentaTr@ining course (hybrid): online modules + expert webinars + in-person workshop in Padova, Italy
🗓 Online Apr–Jul 2026 | Residential Sept 2026
🔗 Register now 👉 penta-id.org/hiv-other-co...
January 20, 2026 at 10:42 AM
📣 Healthcare professionals: level up your expertise in #HIV & congenital infections 🇮🇹!
🎓 PentaTr@ining course (hybrid): online modules + expert webinars + in-person workshop in Padova, Italy
🗓 Online Apr–Jul 2026 | Residential Sept 2026
🔗 Register now 👉 penta-id.org/hiv-other-co...
🎓 PentaTr@ining course (hybrid): online modules + expert webinars + in-person workshop in Padova, Italy
🗓 Online Apr–Jul 2026 | Residential Sept 2026
🔗 Register now 👉 penta-id.org/hiv-other-co...
Reposted by Penta Foundation
Good news for newborn health 👶
New findings from GARDP's #NeoSep1 trial show that off-patent antibiotics, fosfomycin & flomoxef, are safe in newborns with sepsis, supporting affordable treatment options where #AMR burden is highest
🔗 bit.ly/45oK3v1
@pentafoundation.bsky.social
@mrcctu.bsky.social
New findings from GARDP's #NeoSep1 trial show that off-patent antibiotics, fosfomycin & flomoxef, are safe in newborns with sepsis, supporting affordable treatment options where #AMR burden is highest
🔗 bit.ly/45oK3v1
@pentafoundation.bsky.social
@mrcctu.bsky.social
January 9, 2026 at 9:47 AM
Good news for newborn health 👶
New findings from GARDP's #NeoSep1 trial show that off-patent antibiotics, fosfomycin & flomoxef, are safe in newborns with sepsis, supporting affordable treatment options where #AMR burden is highest
🔗 bit.ly/45oK3v1
@pentafoundation.bsky.social
@mrcctu.bsky.social
New findings from GARDP's #NeoSep1 trial show that off-patent antibiotics, fosfomycin & flomoxef, are safe in newborns with sepsis, supporting affordable treatment options where #AMR burden is highest
🔗 bit.ly/45oK3v1
@pentafoundation.bsky.social
@mrcctu.bsky.social
Every year, sepsis claims hundreds of thousands of newborn lives, but new evidence offers hope. 👶
#NeoSep1 Part 1 shows off-patent antibiotics fosfomycin and flomoxef are safe and well tolerated in newborns with suspected #sepsis, including high-risk preterm infants. 💜
👇
#NeoSep1 Part 1 shows off-patent antibiotics fosfomycin and flomoxef are safe and well tolerated in newborns with suspected #sepsis, including high-risk preterm infants. 💜
👇
NeoSep1 Part 1 study shows promising antibiotic options for newborns with suspected sepsis - SNIP-AFRICA
A paper published in the journal Antimicrobial Agents and Chemotherapy (AAC) reports that off-patent antibiotics, fosfomycin and flomoxef, when used at standard doses, were safe in newborn babies with...
www.snip-africa.org
January 9, 2026 at 8:51 AM
On #WorldAIDSDay2025, we recognise the extraordinary efforts of the people who turn evidence into impact, researchers, clinicians and community leaders across the globe.
⬇️
⬇️
December 1, 2025 at 11:43 AM
On #WorldAIDSDay2025, we recognise the extraordinary efforts of the people who turn evidence into impact, researchers, clinicians and community leaders across the globe.
⬇️
⬇️
Old drugs, new hope.
Instead of waiting decades for new antibiotics, #NeoSep1 is rethinking the ones we already have to treat newborn sepsis more safely and effectively. 🩷
In Africa, the trial is a key pillar of #SNIPAFRICA, funded by EDCTP3 and led by Penta. 🔗 snip-africa.org
📰 Guardian feature 👇
Instead of waiting decades for new antibiotics, #NeoSep1 is rethinking the ones we already have to treat newborn sepsis more safely and effectively. 🩷
In Africa, the trial is a key pillar of #SNIPAFRICA, funded by EDCTP3 and led by Penta. 🔗 snip-africa.org
📰 Guardian feature 👇
Antibiotic resistance: how a pioneering trial is using old drugs to save babies from sepsis
The infection is responsible for 800,000 newborn deaths each year, but clinics in eight countries are working together to find new treatments
www.theguardian.com
November 26, 2025 at 8:19 AM
Old drugs, new hope.
Instead of waiting decades for new antibiotics, #NeoSep1 is rethinking the ones we already have to treat newborn sepsis more safely and effectively. 🩷
In Africa, the trial is a key pillar of #SNIPAFRICA, funded by EDCTP3 and led by Penta. 🔗 snip-africa.org
📰 Guardian feature 👇
Instead of waiting decades for new antibiotics, #NeoSep1 is rethinking the ones we already have to treat newborn sepsis more safely and effectively. 🩷
In Africa, the trial is a key pillar of #SNIPAFRICA, funded by EDCTP3 and led by Penta. 🔗 snip-africa.org
📰 Guardian feature 👇
One tablet could change everything.
The UNIVERSAL 1 trial is confirming the right dose for a single, dispersible DTG/FTC/TAF pill for children with #HIV, a formulation prioritised by GAP-f.
Watch for more
#BetterMeds4Kids #WorldChildrensDay #PaediatricHIV #EDCTP
The UNIVERSAL 1 trial is confirming the right dose for a single, dispersible DTG/FTC/TAF pill for children with #HIV, a formulation prioritised by GAP-f.
Watch for more
#BetterMeds4Kids #WorldChildrensDay #PaediatricHIV #EDCTP
World Children's Day 2025
YouTube video by Penta Child Health Research
youtu.be
November 20, 2025 at 12:49 PM
One tablet could change everything.
The UNIVERSAL 1 trial is confirming the right dose for a single, dispersible DTG/FTC/TAF pill for children with #HIV, a formulation prioritised by GAP-f.
Watch for more
#BetterMeds4Kids #WorldChildrensDay #PaediatricHIV #EDCTP
The UNIVERSAL 1 trial is confirming the right dose for a single, dispersible DTG/FTC/TAF pill for children with #HIV, a formulation prioritised by GAP-f.
Watch for more
#BetterMeds4Kids #WorldChildrensDay #PaediatricHIV #EDCTP
Reposted by Penta Foundation
Strengthening paediatric #HIV care in Mozambique: #THRIVE and the Ministry of Health hosted a workshop to improve care for children with advanced HIV disease🌍
@pentafoundation.bsky.social @unitaid.bsky.social
🔗 thriveinfo.org/post/strengthening-paediatric-hiv-care-thrive-ahd-training-in-mozambique
@pentafoundation.bsky.social @unitaid.bsky.social
🔗 thriveinfo.org/post/strengthening-paediatric-hiv-care-thrive-ahd-training-in-mozambique
Strengthening Paediatric HIV Care: THRIVE AHD Training in Mozambique
On 4-5 September 2025, THRIVE project partners convened in Maputo, Mozambique to deliver a targeted two-day training workshop focused on Hospital Care for the Severely Ill Child with Advanced HIV Dise...
thriveinfo.org
November 18, 2025 at 11:14 AM
Strengthening paediatric #HIV care in Mozambique: #THRIVE and the Ministry of Health hosted a workshop to improve care for children with advanced HIV disease🌍
@pentafoundation.bsky.social @unitaid.bsky.social
🔗 thriveinfo.org/post/strengthening-paediatric-hiv-care-thrive-ahd-training-in-mozambique
@pentafoundation.bsky.social @unitaid.bsky.social
🔗 thriveinfo.org/post/strengthening-paediatric-hiv-care-thrive-ahd-training-in-mozambique
On #WorldPneumoniaDay, we share hope for the children battling severe pneumonia.
The PediCAP-A trial showed that it's safe to switch children from IV to oral antibiotics sooner!
✅ Children go home sooner
✅ No more unnecessary IVs & long stays
#PediCAP #ChildHealth #Pneumonia #GlobalHealth
The PediCAP-A trial showed that it's safe to switch children from IV to oral antibiotics sooner!
✅ Children go home sooner
✅ No more unnecessary IVs & long stays
#PediCAP #ChildHealth #Pneumonia #GlobalHealth
November 12, 2025 at 8:20 AM
On #WorldPneumoniaDay, we share hope for the children battling severe pneumonia.
The PediCAP-A trial showed that it's safe to switch children from IV to oral antibiotics sooner!
✅ Children go home sooner
✅ No more unnecessary IVs & long stays
#PediCAP #ChildHealth #Pneumonia #GlobalHealth
The PediCAP-A trial showed that it's safe to switch children from IV to oral antibiotics sooner!
✅ Children go home sooner
✅ No more unnecessary IVs & long stays
#PediCAP #ChildHealth #Pneumonia #GlobalHealth
Incredible nominations are already coming in for #BFA2025 & we can’t wait to celebrate more champions.
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
November 4, 2025 at 8:02 AM
Incredible nominations are already coming in for #BFA2025 & we can’t wait to celebrate more champions.
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
📢 3 weeks to go until the Long COVID Conference 2025! Join us in Boston or online for powerful insights from keynote speakers & expert panelists.
🔗 Final call to register: amededu.co/47cQW3M
Let’s shape the future of Long COVID care together.
#LongCOVIDIntl
@academicmededu.bsky.social
🔗 Final call to register: amededu.co/47cQW3M
Let’s shape the future of Long COVID care together.
#LongCOVIDIntl
@academicmededu.bsky.social
October 29, 2025 at 1:20 PM
📢 3 weeks to go until the Long COVID Conference 2025! Join us in Boston or online for powerful insights from keynote speakers & expert panelists.
🔗 Final call to register: amededu.co/47cQW3M
Let’s shape the future of Long COVID care together.
#LongCOVIDIntl
@academicmededu.bsky.social
🔗 Final call to register: amededu.co/47cQW3M
Let’s shape the future of Long COVID care together.
#LongCOVIDIntl
@academicmededu.bsky.social
Both premature & term newborns in European NICUs are at risk of carrying antibiotic-resistance genes, a key finding from the #NeoIPC feasibility study presented at #jENS2025.
The presenter Chiara Minotti earned 1st prize in the Early Career Investigator session! 👏
View presentation: lnkd.in/dTHrFBnn
The presenter Chiara Minotti earned 1st prize in the Early Career Investigator session! 👏
View presentation: lnkd.in/dTHrFBnn
October 27, 2025 at 1:49 PM
Both premature & term newborns in European NICUs are at risk of carrying antibiotic-resistance genes, a key finding from the #NeoIPC feasibility study presented at #jENS2025.
The presenter Chiara Minotti earned 1st prize in the Early Career Investigator session! 👏
View presentation: lnkd.in/dTHrFBnn
The presenter Chiara Minotti earned 1st prize in the Early Career Investigator session! 👏
View presentation: lnkd.in/dTHrFBnn
🌍 Nominate a grassroots health hero for the 2025 Penta Brighter Future Award.
🏆 €5,000 • ✈️ Italy 2026 • 🤝 Global stage
🗓️ Deadline: 15 Nov → penta-id.org/bfa
#BrighterFutureAward #GlobalHealth
🏆 €5,000 • ✈️ Italy 2026 • 🤝 Global stage
🗓️ Deadline: 15 Nov → penta-id.org/bfa
#BrighterFutureAward #GlobalHealth
October 24, 2025 at 7:38 AM
🌍 Nominate a grassroots health hero for the 2025 Penta Brighter Future Award.
🏆 €5,000 • ✈️ Italy 2026 • 🤝 Global stage
🗓️ Deadline: 15 Nov → penta-id.org/bfa
#BrighterFutureAward #GlobalHealth
🏆 €5,000 • ✈️ Italy 2026 • 🤝 Global stage
🗓️ Deadline: 15 Nov → penta-id.org/bfa
#BrighterFutureAward #GlobalHealth
My name is Jennifer Furin, a Brighter Future Award winner from the United States. There’s no better time to nominate a health hero in your community for this global award.
Nominations close 31 October.
Nominate now: penta-id.org/bfa
#BrighterFutureAward
Nominations close 31 October.
Nominate now: penta-id.org/bfa
#BrighterFutureAward
October 12, 2025 at 1:40 PM
My name is Jennifer Furin, a Brighter Future Award winner from the United States. There’s no better time to nominate a health hero in your community for this global award.
Nominations close 31 October.
Nominate now: penta-id.org/bfa
#BrighterFutureAward
Nominations close 31 October.
Nominate now: penta-id.org/bfa
#BrighterFutureAward
Meet Jose Sumban, the force ensuring the SUPPORT project research is high-quality and reliable!
He coordinates crucial lab efforts against multidrug-resistant infections in children living with HIV & drives key South-to-South collaborations.
Learn more: www.supportproject.eu
He coordinates crucial lab efforts against multidrug-resistant infections in children living with HIV & drives key South-to-South collaborations.
Learn more: www.supportproject.eu
Coordinating critical lab research to combat multidrug-resistance in children living with HIV
YouTube video by Penta Child Health Research
www.youtube.com
October 3, 2025 at 6:59 AM
Meet Jose Sumban, the force ensuring the SUPPORT project research is high-quality and reliable!
He coordinates crucial lab efforts against multidrug-resistant infections in children living with HIV & drives key South-to-South collaborations.
Learn more: www.supportproject.eu
He coordinates crucial lab efforts against multidrug-resistant infections in children living with HIV & drives key South-to-South collaborations.
Learn more: www.supportproject.eu
Can earlier & more frequent follow-ups after hospital discharge save the lives of children with #HIV?
SUPPORT fellow Madania Amorim is exploring this vital question.
Her research aims to improve outcomes via enhanced follow-up.
Learn more: www.supportproject.eu
@globalhealthedctp3.bsky.social
SUPPORT fellow Madania Amorim is exploring this vital question.
Her research aims to improve outcomes via enhanced follow-up.
Learn more: www.supportproject.eu
@globalhealthedctp3.bsky.social
How better follow-up & viral load testing cuts deaths in children living with HIV
YouTube video by Penta Child Health Research
www.youtube.com
September 25, 2025 at 12:22 PM
Can earlier & more frequent follow-ups after hospital discharge save the lives of children with #HIV?
SUPPORT fellow Madania Amorim is exploring this vital question.
Her research aims to improve outcomes via enhanced follow-up.
Learn more: www.supportproject.eu
@globalhealthedctp3.bsky.social
SUPPORT fellow Madania Amorim is exploring this vital question.
Her research aims to improve outcomes via enhanced follow-up.
Learn more: www.supportproject.eu
@globalhealthedctp3.bsky.social
🥳 Recruitment complete! The THAI-CARES RSV Study enrolled 120 children in just 9 weeks, a major milestone for this Penta-sponsored trial across 8 sites in Thailand.
The Phase II study tests remdesivir in children aged 0-2 with RSV-related infections.
👏 Huge thanks to all site teams!
bit.ly/42OubQT
The Phase II study tests remdesivir in children aged 0-2 with RSV-related infections.
👏 Huge thanks to all site teams!
bit.ly/42OubQT
September 24, 2025 at 1:44 PM
🥳 Recruitment complete! The THAI-CARES RSV Study enrolled 120 children in just 9 weeks, a major milestone for this Penta-sponsored trial across 8 sites in Thailand.
The Phase II study tests remdesivir in children aged 0-2 with RSV-related infections.
👏 Huge thanks to all site teams!
bit.ly/42OubQT
The Phase II study tests remdesivir in children aged 0-2 with RSV-related infections.
👏 Huge thanks to all site teams!
bit.ly/42OubQT